DNA Methylation of GSTP1 in Human Prostate Tissues: Pyrosequencing Analysis

Hyung-Yoon Yoon, Young-Won Kim, Ho-Won Kang, Won Tae Kim, Seok-Joong Yun, Sang-Cheol Lee, Wun-Jae Kim, Yong-June Kim

Department of Urology, Chungbuk National University College of Medicine, Cheongju, Korea

**Purpose:** DNA methylation is an important epigenetic mechanism of gene regulation and plays essential roles in tumor initiation and progression. Differences in methylation patterns between neoplastic and normal cells can be used to detect the presence of cancer. The aim of the present study was to evaluate the usefulness of glutathione-S-transferase-Pi (GSTP1) hypermethylation in discriminating between normal and prostate cancer (PCa) cells and in predicting tumor characteristics by use of quantitative pyrosequencing analysis.

**Materials and Methods:** A total of 100 human prostate tissues obtained from our institute were used in this study: 45 for benign prostatic hyperplasia (BPH) and 55 for PCa. The methylation level of GSTP1 was examined by a quantitative pyrosequencing analysis. The associations between GSTP1 methylation level and clinico-pathological parameter were also compared.

**Results:** The level of GSTP1 methylation was significantly higher in PCa samples than in BPH samples (56.7±32.7% vs. 1.6±2.2%, p < 0.001). The sensitivity and specificity of GSTP1 methylation status in discriminating between PCa and BPH reached 85.5% and 100%, respectively. Even after stratification by stage, Gleason score, and prostate-specific antigen (PSA) level, similar results were obtained. A positive correlation between GSTP1 methylation level and serum PSA level was observed (r=0.303, p=0.002). There were no associations between GSTP1 methylation level and age, Gleason score, and staging.

**Conclusions:** Our study demonstrates that GSTP1 methylation is associated with the presence of PCa and PSA levels. This methylation marker is a potentially useful indicator for the detection and monitoring of PCa.

**Key Words:** GSTP1; Methylation; Neoplasms; Prostate

INTRODUCTION

Prostate cancer (PCa) remains a major medical health issue representing one of the frequent cancers among men. The discovery and widespread utilization of serum prostate-specific antigen (PSA) monitoring for early detection has greatly changed the way PCa is diagnosed and has resulted in the downstaging of the disease [1-5]. Active PCa screening with the use of serum PSA level monitoring and digital rectal examination is now widely prevalent in many countries [1,2]. The gold standard for PCa diagnosis is histopathologically reviewed prostatic biopsy cores. This technique, although generally effective, is subject to sampling errors and a significant false-negative rate [1,2]. Thus, the development of new tumor markers with better sensitivity and specificity to detect early cancer remains vitally important.

DNA hypermethylation-induced silencing of tumor suppressor and DNA repair genes is a frequent phenomenon affecting the hallmarks of cancer [6-9]. The genes under-
going methylation during the early phases of tumorigenesis could potentially be used as markers for identifying individuals at increased risk of developing malignancy or for aiding in the diagnosis of early malignancy, whereas those genes undergoing methylation during the progression of malignancy could potentially be used as prognostic markers [6-9]. These hypermethylation markers are promising tools for detecting cancer cells in tissue and body fluids, and various approaches for the detection of aberrant DNA methylation regions have been developed in recent years [7-10].

Most previous studies used methylation-specific polymerase chain reaction (MSP) or quantitative methylation-specific polymerase chain reaction (QMSP) to assess methylation status and often artificially categorized the data into simplistic hypermethylated or hypomethylated categories [7-9]. Despite common use, these methods have known disadvantages such as false-positive and false-negative results as well as the use of relative comparisons instead of absolute quantification [11,12]. To quantify DNA methylation, pyrosequencing (PSQ) is one of the most accurate techniques available [7,11,12].

CpG island methylation of glutathione-S-transferase-Pi (GSTP1) has been detected in several cancer types, including breast and hepatocellular cancer, but only in PCa is this abnormality consistently detected with a high specificity and rarely found in patients without disease [13-18]. The aim of the present study was to evaluate the relevance of GSTP1 methylation status in discriminating between benign prostatic hyperplasia (BPH) and PCa as well as its association with clinico-pathological parameters by use of a quantitative PSQ analysis.

MATERIALS AND METHODS

1. Human tissue samples
A total of 100 human prostate tissue samples obtained from our institute were used in this study: 45 for BPH and 55 for PCa. Patients with PCa underwent radical prostatectomy or palliative transurethral resection (TUR), and patients with BPH underwent TUR. All tissues were macro-dissected within 15 minutes of surgical resection. Each prostate specimen was confirmed by pathological analysis of fresh-frozen sections, and the rest of the tissue was frozen in liquid nitrogen and stored at -80°C until use. The collection and analysis of all samples were approved by the local institutional review board, and informed consent was obtained from each subject.

2. DNA extraction and pyrosequencing analysis
Genomic DNA was extracted by standard methods by use of the Wizard Genomic DNA Purification System (Promega, Madison, WI, USA). Bisulfite modification of genomic DNA (500 ng) was performed with an EZ DNA methylation kit (Zymo Research, Orange, CA, USA) according to the manufacturer’s recommendation. GSTP1 methylation was examined by PSQ. Polymerase chain reaction (PCR) and sequencing primers were designed with PyroMark Assay design ver. 2.0.1.15 (Qiagen, Valencia, CA, USA). The PSQ assay was designed to evaluate the methylation status of seven CpG sites. The total length of the amplicon was 199 bp and the following primers were used: forward 5’-GAGTTAGGAGATTITICAAGAG-3’ and reverse biotinylated 5’-CAATTAACCCCATACTAAAACTCT-3’. The PCR thermal cycling conditions were as follows: denaturation at 94°C for 5 minutes; 45 cycles of 95°C for 30 seconds, 52°C for 30 seconds, and 72°C for 30 seconds; and a final extension at 72°C for 5 minutes. PCR reactions were carried out with 1 μl of bisulfite-converted genomic DNA for all prostate tissues. A biotin-labeled primer (reverse primer) was used to purify PCR product by use of streptavidin-coated Sepharose beads (GE Healthcare, Buckinghamshire, UK). PCR product was bound to Sepharose beads, purified, washed, denatured by using a 0.2 mol/l NaOH solution, and washed again. Then 0.3 μmol/l pyrosequencing primer (5’-GGGGAGGGATTITITATAAGG-3’) was annealed to the purified single-stranded PCR product and the pyrosequencing was performed on a PyroMark Q96 ID (Qiagen) according to the manufacturer’s instructions. To provide the internal control for total bisulfite conversion, a non-CG cytosine in the region for PSQ was included where possible. Target CpG sites were evaluated by use of instrument software (PSQ96MA 2.1, Qiagen) that converts the pyrograms to numerical values for peak heights and calculates the proportion of methylation at each base as a C/T ratio. Data analysis was performed by using PyroMark Q96 ID ver. 1.0 (Qiagen).

3. Statistical analysis
We compared the quantitative GSTP1 methylation level and its association with clinico-pathological characteristics in BPH and PCa patients. The methylation level of each sample was expressed as the mean value (the sum of the methylation level of each CpG site, n=7). The differences in continuous variables between the groups were assessed by use of two-sample t-tests. Categorical variables were compared by using the chi-square test. The optimal sensitivity and specificity with DNA methylation of GSTP1 for discriminating between PCa and BPH was determined by receiver operator characteristic (ROC) curve analysis by use of MedCalc software (MedCalc Software, Mariakerke, Belgium). The area under the ROC curve and the methylation threshold yielding the optimal sensitivity and specificity for the prediction of PCa were calculated. By use of the same thresholds, the sensitivity, specificity, positive predictive value, and negative predictive value were also calculated. Pearson’s correlation was used to evaluate the relation between the GSTP1 methylation level and clinico-pathological parameters. Tests for trend were performed by analysis of variance trend analyses by using polynomial contrasts. For statistical purposes, PCa patients were divided into subgroups according to the following clinico-pathological parameters: 1) Gleason score (GS ≤6, GS=7, and GS ≥8), 2) stage (T2, T3, and T4), and 3) PSA level at diagnosis (PSA <10, 10 to 20, and ≥20 ng/ml).

Korean J Urol 2012;53:200-205
Statistical analysis was performed by using SPSS ver. 12.0 (SPSS Inc., Chicago, IL, USA), and a p-value of <0.05 was considered statistically significant.

RESULTS

1. Baseline characteristics
The baseline characteristics of the patients are presented in Table 1. The mean age and total prostate volume were not significantly different between the BPH and PCa groups. PCa patients had elevated levels of PSA compared with BPH patients.

2. Methylation level in prostate tissues
Fig. 1 shows an example of the pyrograms in BPH and PCa patients. The methylation level of GSTP1 was significantly higher in PCa samples than in BPH samples (56.7±32.7% vs. 1.6±2.2%, p<0.001) (Fig. 2A). In the ROC analysis, the area under the curve of the GSTP1 methylation level for the prediction of PCa reached 0.908 (95% confidence interval [CI], 0.834 to 0.957) (Fig. 2B). For well-balanced sensitivity and specificity, the GSTP1 methylation value corresponded to a cutoff of 13.3%. That cutoff showed 85.5% sensitivity (95% CI, 73.3 to 93.5%), 100% specificity (95% CI, 92.1 to 100%), 100% positive predictive value (95% CI, 92.5 to 100%), and 84.9% negative predictive value (95% CI, 72.3 to 93.3%), respectively. Patients were divided into hypermethylated and unmethylated groups by use of a cutoff level. As presented in Table 2, GSTP1 was methylated in 85.5% (47/55) and 0% (0/45) of PCa and BPH samples, respectively. Similar results were obtained even after stratification by PSA level, stage, and Gleason score.

3. Association between methylation level and clinico-pathological parameters in PCa patients
To evaluate the relation between GSTP1 methylation level and clinico-pathological parameters, we performed a correlation analysis. No correlation was found between GSTP1 methylation level and age (r=0.077, p=0.445) or Gleason score (r=-0.025, p=0.859). In contrast, we found a positive correlation between GSTP1 methylation level and serum PSA level (r=0.303, p=0.002). We also compared the GSTP1 methylation levels on the basis of the corresponding clinico-pathological parameters (Gleason score [GS ≤ 6, GS=7, and GS ≥ 8], stage [T2, T3, T4], and PSA level [PSA <10, 10 to 20, ≥ 10 ng/ml]). GSTP1 methylation levels increased similarly with increasing PSA level (p trend <0.001) (Fig. 3), whereas no trend was found between GSTP1 methylation level and Gleason score or stage (p trend >0.05, respectively).

DISCUSSION
Our results demonstrated that the methylation level of GSTP1 was significantly higher in PCa patients than in
**FIG. 2.** (A) GSTP1 methylation level in benign prostatic hyperplasia (BPH) and prostate cancer (PCa) patients. Differences (p-value) between BPH and PCa patients were obtained by two-sample t-test. The y axis indicates the absolute methylation expression level of GSTP1. (B) Receiver operator characteristic (ROC) curve analysis of GSTP1 methylation for PCa prediction.

**TABLE 2.** Frequency of GSTP1 methylation in human prostate tissues

|                | BPH (n=45) | PCa (n=55) |
|----------------|------------|------------|
| Methylation ratea | 0 (0/45)   | 85.5 (47/55) |
| PSA level (ng/ml)  |             |            |
| <10             | 0 (0/40)   | 62.5 (5/8)  |
| 10–20           | 0 (0/3)    | 66.7 (4/6)  |
| ≥20             | 0 (0/2)    | 92.7 (38/41) |
| T staging       |            |            |
| T2              | -          | 81.5 (22/27) |
| T3              | -          | 83.3 (15/18) |
| T4              | -          | 100 (10/10) |
| Gleason score   |            |            |
| ≤6              | -          | 100 (4/4)   |
| 7               | -          | 84.2 (16/19) |
| ≥8              | -          | 84.4 (27/32) |

BPH, benign prostatic hyperplasia; PCa, prostate cancer; PSA, prostate-specific antigen.

a: Methylation rate is expressed as percentage (no. of methylated samples/total number of samples).

**FIG. 3.** GSTP1 methylation level according to the prostate-specific antigen (PSA) level. Differences (p-value) among groups were calculated by analysis of variance trend analyses. The y axis indicates the absolute methylation expression level of GSTP1.

**BPH patients. Moreover, GSTP1 hypermethylation was not only associated with an increased incidence of PCa, but was positively related to increases in the PSA level. In contrast, no significant relationships between GSTP1 methylation and age, stage, or Gleason score were established.**

Methylation of a promoter region has been shown to be associated with suppression of gene transcription, and hence gene expression. CpG island methylation is thought to influence transcription by allowing the attachment of methyl-binding domain proteins, which indirectly block the binding of transcription factors [7-9,14]. Abnormal DNA methylation patterns are associated with many human tumor types, and differences in methylation patterns have also emerged as markers for cancer risk assessment, cancer diagnosis, and therapy monitoring in several different types of cancer [7-9]. Moreover, DNA methylation for cancer detection is quite powerful owing to the inherent stability of DNA compared with RNA or protein [8]. To date, aberrant methylation of CpG island-containing promoters of numerous hypermethylated loci including GSTP1 has been identified in PCa [7,10,14]. However, even in the same gene, the inconsistency of methylation levels reported in PCa could be the result of several factors, not the least of which is the different sample types used [7,13,14]. The variation could also be a result of different analytical methods and how they are applied, including the pretreatment of the DNA, the PCR conditions, and the PCR method. Recently, with technical developments, various methods have become available for the detection of the methylation status of certain genes in clinical samples [7,8]. Conventional MSP has been shown to have limited usefulness for specific cancer detection because benign lesions can be weakly pos-
itive and cannot be distinguished from cancer cases. Moreover, the results of MSP at a particular DNA region are simply reported as methylated or unmethylated, which may be also subjective, thus not allowing quantitation or identification of partial methylation. For improvement of sensitivity and quantitation, various techniques, such as nested two-stage PCR and QMSP, have been developed. However, these methods also have known drawbacks, such as false-positive and false-negative results, as well as the use of relative comparisons instead of absolute quantification [7,8,11,12]. In these regards, PSQ might be a best alternative tool, because it provides absolute quantitative information on bases at each interrogated CG site. Additionally, the assay design readily allows the interrogation of different parts of the gene(s) of interest as well as the inclusion of internal controls to address inaccuracies resulting from incomplete bisulfite conversion [7,11,12]. In the present study, we utilized PSQ to evaluate methylation status, and provided an optimal cutoff level to discriminate between PCa and normal controls. Our provided cutoff level was relatively low; thus, it might be misleading with the use of other techniques [7,11,12]. One of the major advantages of PSQ is the ability to quantitatively compare samples and to more accurately segregate varied pathologic covariates on the basis of methylation levels. If we did not use PSQ, we would not have found the significant correlation between \textit{GSTP1} methylation and PSA level.

\textit{GSTP1} is involved in the metabolism, detoxification, and elimination of potentially genotoxic foreign compounds, and thus acts to protect cells from DNA damage and cancer initiation. Suppression of \textit{GSTP1} activity can result in enhanced susceptibility to DNA damage and increased cancer incidence [13,14]. Many works have been reported on the development of \textit{GSTP1} methylation as a biomarker that could be used to detect PCa [13-18]. Most studies have reported a consistent link between \textit{GSTP1} methylation and PCa. Although the strength of the association has varied, in tissue samples taken by biopsy or during surgery, \textit{GSTP1} methylation has been detected in at least 70% of cases and is only rarely present in benign prostate tissue [13-18]. As previously mentioned, various reasons exist for this inconsistency in \textit{GSTP1} methylation levels, including the detection methods and different tissue types used. Our findings are consistent with these previous results and indicate that \textit{GSTP1} hypermethylation is a reliable indicator for the prediction of PCa.

Although histologically confirmed prostate tissues were used, the possibility of unrevealed PCa in BPH patients and a small fraction of undetected methylated DNA molecules might have affected our results for sensitivity and specificity. Nonetheless, in terms of methylation frequency, our results are promising. The sensitivity and specificity of \textit{GSTP1} methylation in distinguishing PCa and benign tissue reached 85.5% and 100%, respectively. Moreover, the frequency of \textit{GSTP1} methylation in PCa was independent of serum PSA level, Gleason score, and stage. Clearly, biopsy has no potential as a routine screening test because of its highly invasive nature. Although these findings are promising, multicenter, large-scale clinical validation studies with primary human cancer tissue and body fluids are currently underway at our institute to confirm \textit{GSTP1} as a diagnostic PCa methylation marker. These kinds of efforts will improve our understanding of the role of \textit{GSTP1} methylation in tumorigenesis and its clinical relevance.

CONCLUSIONS

The results of our study show that \textit{GSTP1} methylation is associated with the presence of PCAs and PSA levels. This methylation marker represents a potentially useful indicator for the detection and monitoring of PCAs.

CONFLICTS OF INTEREST

The authors have nothing to disclose.

ACKNOWLEDGEMENTS

This work was supported by a research grant of the Chungbuk National University in 2010.

REFERENCES

1. Greene KL, Albertsen PC, Babian RJ, Carter HB, Gann PH, Han M, et al. Prostate specific antigen best practice statement: 2009 update. J Urol 2009;182:2232-41.
2. Schröder F, Kattan MW. The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review. Eur Urol 2008;54:274-90.
3. Kim HW, Ko YH, Kang SH, Lee JG. Predictive factors for prostate cancer in biopsy of patients with prostate-specific antigen levels equal to or less than 4 ng/ml. Korean J Urol 2011;52:166-71.
4. Seo HS, Lee NK. Predictors of PSA screening among men over 40 years of age who had ever heard about PSA. Korean J Urol 2010;51:391-7.
5. Yang JB, Jeong BC, Seo SI, Jeon SS, Choi HY, Lee HM. Outcome of prostate biopsy in men younger than 40 years of age with high prostate-specific antigen (PSA) levels. Korean J Urol 2010;51:214.
6. van Vlodrop IJ, Niessen HE, Derks S, Baldewijns MM, van Criekinge W, Herman JG, et al. Analysis of promoter CpG island hypermethylation in cancer: location, location, location! Clin Cancer Res 2011;17:4225-31.
7. Hoque MO. DNA methylation changes in prostate cancer: current developments and future clinical implementation. Expert Rev Mol Diagn 2009;9:243-57.
8. Ushijima T. Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 2005;5:223-31.
9. Kim WJ, Kim YJ. Epigenetic biomarkers in urothelial bladder cancer. Expert Rev Mol Diagn 2009;9:259-69.
10. Kim YJ, Yoon HY, Kim SK, Kim YW, Kim EJ, Kim IY, et al. EFEMP1 as a novel DNA methylation marker for prostate cancer: array-based DNA methylation and expression profiling. Clin Cancer Res 2011;17:4523-30.
11. Marsh S. Pyrosequencing applications. Methods Mol Biol 2007;373:15-24.
12. Vasiljevic NA, Wu K, Brentnall AR, Kim DC, Thorat MA, Kudahetti SC, et al. Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing.
Dis markers 2011;30:151-61.
13. Phe V, Cussenot O, Roupret M. Methylated genes as potential biomarkers in prostate cancer. BJU Int 2010;105:1364-70.
14. Hopkins TG, Burns PA, Routledge MN. DNA methylation of GSTP1 as biomarker in diagnosis of prostate cancer. Urology 2007;69:11-6.
15. Gonzalgo ML, Nakayama M, Lee SM, De Marzo AM, Nelson WG. Detection of GSTP1 methylation in prostatic secretions using combinatorial MSP analysis. Urology 2004;63:414-8.
16. Alumkal JJ, Zhang Z, Humphreys EB, Bennett C, Mangold LA, Carducci MA, et al. Effect of DNA methylation on identification of aggressive prostate cancer. Urology 2008;72:1234-9.
17. Ellinger J, Bastian PJ, Jurgan T, Biemann K, Kahl P, Heukamp LC, et al. CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology 2008;71:161-7.
18. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Plantadosi S, Walsh PC, et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004;64:1975-86.